Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 88495-63-0] Artesunate

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-N0193
Brand:	MCE
CAS:	88495-63-0

Overview

MDL	MFCD00866204
Molecular Weight	384.42
Molecular Formula	C19H28O8
SMILES	O=C(O[C@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1)CCC(O)=O

For research use only. We do not sell to patients.

9 Publications Citing Use of MCE

[1]J Neurochem. 2022 May 21.
[2]Front Mol Neurosci. 2022 May 27;15:902572.
[3]Int Immunopharmacol. 2021 Apr 29;97:107705.
[4]Chem Biol Interact. 2020 Nov 1;331:109273.
[5]Drug Des Devel Ther. 2019 Jul 2;13:2135-2144.
[6]Diagnostics (Basel). 2021 Feb 26;11(3):395.
[7]Neuroscience. 2022 Jan 10;S0306-4522(22)00003-3.
[8]Basic Clin Pharmacol Toxicol. 2022 Nov 26.
[9]Research Square Print. November 28th, 2022.

Summary

Artesunate is an inhibitor of both STAT-3 and exported protein 1 ( EXP1 ).

IC50 & Target

Stat-3

EXP1

In Vitro

Artesunate is an inhibitor of both STAT-3 ^[1] and exported protein 1 (EXP1) ^[2] . Artesunate treatment for 24 h causes a significant increase in the levels of reactive oxygen species (ROS) in a dose-dependent manner in both cell lines. Moreover, Western blotting shows that the levels ofγ-H2AX are significantly elevated when cancer cells are treated with Artesunate in the higher dose range for 24 h. Artesunate also shows a time-dependent effect on the level of RAD51 in A2780 and HO8910 cells. In two types of non-malignant cells, normal human fibroblasts and immortalized epithelial cells, FTE-187, the level of RAD51 is not altered by Artesunate. In A2780 cells, the level of RAD51 mRNA is indeed decreased by the addition of Artesunate, in a dose-dependent manner. Correspondingly, the promoter activity of RAD51 is significantly inhibited by Artesunate. In contrast, the RAD51 mRNA level in H8910 cells is not affected by Artesunate ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tumor growth is significantly reduced in the group receiving combined treatment of Artesunate and cisplatin (P<0.01). In comparison, Artesunate alone has no significant effect on the growth of tumor xenografts for both cell lines ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03726593	Armed Forces Research Institute of Medical Sciences, Thailand\|National Center for Parasitology, Entomology, and Malaria Control (CNM)\|Naval Medical Research Unit-2 (NAMRU-2)	Plasmodium Falciparum Malaria (Drug Resistant)	October 4, 2018	Phase 4
NCT01122134	Makerere University	Severe Malaria	May 2010
NCT01115439	University of Oxford\|National Malaria and Leishmaniasis Control Program, Afghanistan\|World Health Organization	Falciparum Malaria	March 2010
NCT00509015	Radboud University Medical Center\|Kilimanjaro Christian Medical Centre, Tanzania\|London School of Hygiene and Tropical Medicine	Malaria, Falciparum	February 2008	Not Applicable
NCT01662700	Mahidol University	Acute Uncomplicated Malaria With P.Vivax Infection	October 2012	Phase 4
NCT00132548	London School of Hygiene and Tropical Medicine\|Institut de Recherche pour le Developpement, Senegal\|Cheikh Anta Diop University, Senegal\|Ministry of Health, Senegal	Malaria	June 2004	Phase 3
NCT02663700	National Institute of Allergy and Infectious Diseases (NIAID)	Plasmodium Falciparum Infection	April 7, 2016	Phase 1
NCT03792516	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Frantz Viral Therapeutics, LLC	Vulvar Dysplasia\|HPV-Related Vulvar Intraepithelial Neoplasia\|Preinvasive Vulvar Disease\|Vulva Intraepithelial Neoplasia\|Vulvar Diseases	April 17, 2019	Phase 1
NCT03893097	Institute of Tropical Medicine, Belgium\|Institut de Recherche en Santé, de Surveillance �pidémiologique et de Formation (IRESSEF)	Schistosoma Haematobium\|Schistosoma Mansoni	October 14, 2019	Phase 3
NCT01082731	Centers for Disease Control and Prevention	Malaria	November 2010	Phase 4
NCT00146731	London School of Hygiene and Tropical Medicine\|National Institute for Medical Research, Tanzania	Malaria	January 2004	Phase 3
NCT02353026	Georgetown University\|United States Department of Defense	Solid Tumors	January 2015	Phase 1
NCT00203801	University of Cape Town\|World Health Organization\|Medical Research Council, South Africa\|Global Fund	Malaria	January 2002	Not Applicable
NCT03100045	Johns Hopkins University\|Frantz Viral Therapeutics, LLC\|University of Wisconsin, Madison	HPV-Related Anal Intraepithelial Neoplasia\|AIN2+3\|Artesunate\|Alternative Treatment\|Anal Dysplasia\|Precancerous Conditions\|Human Papilloma Virus	April 20, 2017	Phase 1
NCT02563704	University of Yaounde 1	Malaria	September 2013	Phase 3
NCT00445796	Sanofi	Malaria	June 2005	Phase 4
NCT00694694	London School of Hygiene and Tropical Medicine\|National Institute for Medical Research, Tanzania	Malaria	June 2008	Phase 3
NCT04387240	Princess Nourah Bint Abdulrahman University	Covid 19 Positive\|Corona Virus Infection	January 2022	Phase 2
NCT01319448	London School of Hygiene and Tropical Medicine\|Medical Research Council Unit, The Gambia\|Wellcome Trust\|University of Ilorin Teaching Hospital	Malaria\|Sickle Cell Crisis	September 2011	Phase 1\|Phase 2
NCT00373607	Institute of Tropical Medicine, Belgium	Malaria	July 2003	Phase 3
NCT00374205	Bernhard Nocht Institute for Tropical Medicine\|Presbyterian Health Service (PHS)\|Kumasi Centre for Collaborative Research (KCCR)\|School of Medical Sciences Kumasi (SMS+KNUST)	Malaria, Falciparum	September 2006	Phase 4
NCT01955382	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Malaria\|Severe Malaria	September 2013	Phase 2
NCT01976780	Global Emerging Infections Surveillance and Response System\|United States Army Medical Unit - Kenya\|Walter Reed Army Institute of Research (WRAIR)	Malaria	June 2013	Phase 4
NCT03201770	Shin Poong Pharmaceutical Co. Ltd.\|Medicines for Malaria Venture	Malaria,Falciparum	June 22, 2017	Phase 4
NCT01107145	Centers for Disease Control and Prevention	Plasmodium Vivax Malaria	February 2011	Phase 4
NCT00422084	Medicines for Malaria Venture\|Shin Poong Pharmaceuticals	Malaria	January 2007	Phase 3
NCT05273242	Nepal Health Research Council\|World Health Organization	COVID-19	December 6, 2021	Phase 4
NCT00158548	London School of Hygiene and Tropical Medicine\|World Health Organization\|HealthNet TPO\|United Nations High Commissioner for Refugees\|Malaria Control Program, Directorate of Malaria Control, Pakistan	Malaria\|Falciparum Malaria\|Vivax Malaria	June 2001	Phase 3
NCT04098744	Frantz Viral Therapeutics, LLC\|Amarex Clinical Research\|M.D. Anderson Cancer Center\|Harris Health System (L.B.J. Hospital)\|The Cleveland Clinic\|University of Michigan\|Morehouse School of Medicine	CIN 2+3\|HPV Infection\|Pre-Cancerous Dysplasia\|Cervical Dysplasia\|HPV Related Disease	September 9, 2020	Phase 2
NCT05441410	University Hospital Tuebingen\|Sanaria Inc.\|University of Oxford	Malaria	October 1, 2022	Phase 1\|Phase 2
NCT02304289	University Hospital, Ghent\|University Ghent\|Anticancer Fund, Belgium	Hepatocellular Carcinoma	November 2014	Phase 1
NCT03814616	Shin Poong Pharmaceutical Co. Ltd.\|Medicines for Malaria Venture	Malaria,Falciparum	October 3, 2018	Phase 2
NCT04706130	University of Maryland, Baltimore\|National Centre for Parasitology, Entomology and Malaria Control, Cambodia\|Institut Pasteur du Cambodge	Vivax Malaria	April 15, 2021	Phase 4
NCT00959517	London School of Hygiene and Tropical Medicine\|HealthNet TPO	Uncomplicated Falciparum Malaria	July 2001	Phase 2
NCT00538382	NICHD Global Network for Women´s and Children´s Health\|Global Network for Women´s and Children´s Health Research\|Bill and Melinda Gates Foundation\|Fogarty International Center of the National Institute of Health\|National Center for Complementary and Integrative Health (NCCIH)\|National Institute of Dental and Craniofacial Research (NIDCR)\|National Cancer Institute (NCI)\|RTI International\|University of North Carolina\|Kinshasa School of Public Health	Malaria	May 2007	Phase 1
NCT02640495	University of Oxford\|Mahidol Oxford Tropical Medicine Research Unit\|Oxford University Clinical Research Unit, Vietnam	Malaria	October 2015
NCT01144702	Oswaldo Cruz Foundation\|Pan American Health Organization\|Ministry of Health, Brazil\|University of Sao Paulo	Falciparum Malaria	November 2010	Phase 2\|Phase 3
NCT04374019	Susanne Arnold\|University of Kentucky	COVID\|Sars-CoV2	May 1, 2020	Phase 2
NCT01023399	Sanofi\|Medicines for Malaria Venture	Malaria	November 2009	Phase 4
NCT01165372	Oxford University Clinical Research Unit, Vietnam\|World Health Organization	Malaria	August 2010	Phase 2
NCT00164359	Centers for Disease Control and Prevention\|Ministry of Health and Population, Malawi	Malaria, Falciparum	April 2005	Phase 4
NCT00164255	Centers for Disease Control and Prevention\|Ifakara Health Research and Development Centre	Malaria	January 2003	Phase 4
NCT01074905	University of Oxford\|Mahidol University	Vivax Malaria	May 2010	Phase 3
NCT00936767	University of Oxford\|Mahidol University\|Medicines for Malaria Venture	Uncomplicated Falciparum Malaria	October 2010	Phase 2\|Phase 3
NCT04368910	Medicines for Malaria Venture\|Shin Poong Pharmaceuticals	Malaria	September 6, 2007	Phase 3
NCT00541385	Medicines for Malaria Venture\|Shin Poong Pharmaceuticals	Malaria	October 2007	Phase 3
NCT00894374	Pfizer	Falciparum Malaria	June 2009	Phase 1
NCT01378286	Sanofi	Malaria	January 2012	Phase 3
NCT01082718	Centers for Disease Control and Prevention	Malaria\|Pregnancy	March 2010	Phase 2\|Phase 3
NCT01707199	University of Oxford\|World Health Organization	Uncomplicated P. Falciparum Malaria	October 2012	Not Applicable
NCT00612547	National Malaria Control Programme, Madagascar\|Population Services International\|Reggio Terzo Mondo\|Santé Net\|Inter Aide Santé,\|Adventist Development and Relief Agency\|SAF FJKM\|Sanofi\|Institut Pasteur de Madagascar	Fever\|Suspected Malaria	February 2008
NCT00356005	Medical University of Vienna\|International Centre for Diarrhoeal Disease Research, Bangladesh\|Armed Forces Research Institute of Medical Sciences, Thailand	Uncomplicated Falciparum Malaria	August 2006	Phase 2
NCT00292942	U.S. Army Medical Research and Development Command\|Walter Reed Army Institute of Research (WRAIR)	Malaria\|Malaria, Cerebral	June 12, 2006	Phase 1
NCT00203814	University of Cape Town\|World Health Organization\|Medical Research Council, South Africa	Malaria	January 2004	Not Applicable
NCT00764036	Heidelberg University\|Hector-Stiftung\|Dafra Pharma\|Monika-Kutzner Stiftung, Berlin, Germany\|HEIFAN-Heidelberger Förderverein d. Ambulanz f. Naturheilkunde eV, Heidelberg, Germany	Metastatic Breast Cancer\|Locally Advanced Breast Cancer	October 2008	Phase 1
NCT00284687	Hadassah Medical Organization\|Institut für Klinische und Molekulare Virologie\|University of Erlangen-Nürnberg Medical School	Cytomegalovirus Infections	July 2006	Phase 3
NCT00639873	Medical University of Vienna\|International Centre for Diarrhoeal Disease Research, Bangladesh\|World Health Organization	Malaria	June 2008	Not Applicable
NCT05555862	Frantz Viral Therapeutics, LLC\|Amarex CRO\|University of California, San Francisco\|Anal Dysplasia Clinic MidWest\|Laser Surgery Care	Anal High Grade Squamous Intraepithelial Lesion\|Anal Precancerous Condition\|AIN 2+3\|HPV Infection\|Anal Dysplasia\|HPV Disease	November 15, 2022	Phase 2
NCT00875030	Pfizer	Healthy Volunteers	June 2009	Phase 4
NCT00299208	National Institute of Allergy and Infectious Diseases (NIAID)	Plasmodium Falciparum Malaria		Phase 2
NCT00118807	London School of Hygiene and Tropical Medicine\|Medical Research Council\|National Malaria Control Programme, The Gambia	Malaria	August 2003	Phase 3
NCT00682630	Medicines for Malaria Venture\|Shin Poong Pharmaceuticals	Malaria	September 2007	Phase 1
NCT00298610	U.S. Army Medical Research and Development Command\|Military Infectious Diseases Research Program (MIDRP)	Malaria	March 2006	Phase 2
NCT01939886	London School of Hygiene and Tropical Medicine\|Kilimanjaro Christian Medical Centre, Tanzania\|Radboud University Medical Center\|European Union	Malaria	April 2013	Phase 3
NCT01350856	University of Oxford\|Mahidol University\|Worldwide Antimalarial Resistance Network	Falciparum Malaria	May 2011	Phase 4
NCT00461578	London School of Hygiene and Tropical Medicine\|Institute of Tropical Medicine, Belgium	Malaria	April 2005	Not Applicable
NCT01523002	Medicines for Malaria Venture\|Shin Poong Pharmaceuticals	Malaria	January 2012	Phase 1
NCT02084602	Instituto Nacional de Salud. Peru\|U.S. Naval Medical Research Unit No.6 (NAMRU-6)	Malaria, Falciparum	June 18, 2014	Phase 4
NCT02354534	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Frantz Viral Therapeutics	Cervical Intraepithelial Neoplasia Grade 2+3\|High-risk HPV (Any Strain)	February 2015	Phase 1
NCT01374126	Medical University of Vienna\|International Centre for Diarrhoeal Disease Research, Bangladesh	Falciparum Malaria	July 2011	Phase 2
NCT02653898	Armed Forces Research Institute of Medical Sciences, Thailand\|National Center for Parasitology, Entomology, and Malaria Control (CNM)\|Ministry of National Defense, Royal Cambodian Armed Forces Department of Health	Malaria\|Parasitic Diseases	January 2016	Phase 4
NCT00459615	U.S. Army Office of the Surgeon General\|Military Infectious Diseases Research Program (MIDRP)\|U.S. Army Medical Research and Development Command\|Walter Reed Army Institute of Research (WRAIR)	Falciparum Malaria\|Uncomplicated Malaria	April 2007	Phase 2
NCT04921930	Institut National de la Santé Et de la Recherche Médicale, France\|Imagine Institute	Friedreich Ataxia	July 1, 2021	Phase 1\|Phase 2
NCT00140361	Centers for Disease Control and Prevention\|United States Agency for International Development (USAID)	Malaria (Uncomplicated)	January 2000	Phase 4
NCT03431714	National Institute for Medical Research, Tanzania\|Muhimbili University of Health and Allied Sciences\|World Health Organization	Uncomplicated Falciparum Malaria	July 14, 2017	Phase 4
NCT00354380	Heidelberg University	Malaria	September 2006	Phase 2
NCT00493363	University of Oxford\|World Health Organization\|NCHADS - Ministry of Health of Cambodia\|Mahidol University\|Institut Pasteur\|FHI 360\|Li Ka Shing Foundation	Falciparum Malaria	June 2007	Not Applicable
NCT00111163	Centers for Disease Control and Prevention\|Kenya Medical Research Institute\|Bill and Melinda Gates Foundation	Malaria\|Anemia	March 2004	Not Applicable
NCT00479206	Medical University of Vienna\|Global Emerging Infections Surveillance and Response System\|Armed Forces Research Institute of Medical Sciences, Thailand\|National Center for Parasitology, Entomology and Malaria Control	Malaria, Falciparum	October 2006	Not Applicable
NCT00403260	Medicines for Malaria Venture\|Shin Poong Pharmaceuticals	Falciparum Malaria	January 2007	Phase 3
NCT00440999	Medicines for Malaria Venture\|Shin Poong Pharmaceuticals	Malaria	March 2007	Phase 3
NCT04675931	Novartis Pharmaceuticals\|Wellcome Trust\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|Novartis	Severe Malaria	March 7, 2022	Phase 2
NCT00486694	London School of Hygiene and Tropical Medicine	Malaria, Vivax	March 2004	Phase 2
NCT00378625	Centro Internacional de Entrenamiento e Investigaciones Médicas\|World Health Organization\|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)	Malaria,Falciparum\|Malaria\|Antimalarials	April 2000	Phase 3
NCT00164216	Centers for Disease Control and Prevention\|National Institute of Health, Peru	Malaria Falciparum	March 2005
NCT00722150	Armed Forces Research Institute of Medical Sciences, Thailand\|World Health Organization\|Bill and Melinda Gates Foundation	Falciparum Malaria	July 2008	Not Applicable
NCT02492178	University of Oxford\|Kinshasa School of Public Health	Malaria	July 2015	Phase 2
NCT00432367	London School of Hygiene and Tropical Medicine\|Kwame Nkrumah University of Science and Technology	Malaria\|Anaemia\|Pregnancy	February 2007	Phase 3
NCT00292929	U.S. Army Medical Research and Development Command	Malaria\|Malaria, Cerebral		Phase 1
NCT00452907	Sanofi	Malaria	July 2005	Phase 4
NCT00978172	Mepha Ltd.\|Centre Mère et Enfant de la Fondation Chantal Biya	Malaria	December 2007	Phase 4
NCT03214731	Sun Yat-sen University\|The First People´s Hospital of Yunnan\|The First Affiliated Hospital of Nanchang University\|General Hospital of Ningxia Medical University\|First Affiliated Hospital of Fujian Medical University\|Shenzhen Second People´s Hospital\|The Third Xiangya Hospital of Central South University\|Tongji Hospital	Lupus Nephritis	January 16, 2019	Phase 4
NCT00331708	Professor Karen I Barnes\|Global Fund\|Medical Research Council, South Africa\|University of Cape Town	Malaria	April 2006	Not Applicable
NCT00522132	Medicines for Malaria Venture\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|Severe Malaria in African Children Consortium	Malaria	September 2007	Phase 2
NCT00287300	University of North Carolina\|Centers for Disease Control and Prevention\|University of North Carolina, Chapel Hill	Malaria	September 2003	Not Applicable
NCT04330690	Sunnybrook Health Sciences Centre\|AbbVie\|Apotex Inc.\|World Health Organization\|University of British Columbia\|Arch Biopartners Inc.	COVID-19	March 18, 2020	Phase 3
NCT00386503	Sanofi	Malaria	June 2006	Phase 1
NCT00203736	University of Cape Town\|World Health Organization\|Medical Research Council, South Africa\|Global Fund	Malaria	January 2003	Not Applicable
NCT02092766	University of Oxford\|Kinshasa School of Public Health	Anaemia	June 2014	Phase 4
NCT04713631	Sanjay Gandhi Postgraduate Institute of Medical Sciences\|St George´s University of London, London, UK	Crohn´s Disease	January 21, 2021	Phase 2
NCT00988507	Sanofi	Plasmodium Falciparum Infection	October 2009	Phase 2
NCT01659281	Armed Forces Research Institute of Medical Sciences, Thailand	Plasmodium Falciparum Malaria	September 2007	Not Applicable
NCT01407887	Heidelberg University	Uncomplicated Falciparum Malaria	August 2011	Phase 2
NCT00465257	Karolinska University Hospital	Malaria	May 2007	Phase 4
NCT00289250	London School of Hygiene and Tropical Medicine\|Medical Research Council Unit, The Gambia	Asymptomatic P.Falciparum Malaria	May 2001	Phase 3
NCT00379821	National Institute of Allergy and Infectious Diseases (NIAID)	Plasmodium Falciparum Infection	February 2007	Phase 3
NCT01190371	KEMRI-Wellcome Trust Collaborative Research Program\|University of Oxford\|Heidelberg University	Malaria	April 2011	Phase 4
NCT03093129	The 108 Military Central Hospital\|Institute of Tropical Medicine, University of Tuebingen	Colorectal Cancer	January 8, 2018	Phase 2
NCT00356824	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Malaria	November 2005
NCT00316329	Sanofi	Malaria	March 2006	Phase 3
NCT00550160	Kwame Nkrumah University of Science and Technology\|Department for International Development, United Kingdom\|Malaria Consortium, UK\|Center for International Health and Development	Malaria	April 2007	Phase 4
NCT02604966	National Institute of Malariology, Parasitology and Entomology, Vietnam\|Institute of Tropical Medicine, Belgium	Drug Resistant Malaria Due to Plasmodium Falciparum	April 2015	Phase 4
NCT02996695	National Institute of Allergy and Infectious Diseases (NIAID)	Plasmodium Falciparum Infection	April 6, 2017	Phase 1
NCT00164710	Centers for Disease Control and Prevention\|Ministry of Health and Population, Malawi	Malaria, Falciparum	April 2005	Phase 4
NCT03764527	Professor Anders Björkman\|Zanzibar Malaria Control Programme\|World Health Organization\|Karolinska Institutet	Plasmodium Falciparum Malaria	November 1, 2002	Phase 4
NCT01152931	University of Lagos, Nigeria	Malaria	August 2010	Phase 3
NCT02633098	St George´s, University of London	Colorectal Cancer\|Bowel Cancer	April 26, 2017	Phase 2
NCT03768908	Professor Anders Björkman\|Zanzibar Malaria Control Programme\|Karolinska Institutet	Plasmodium Falciparum Malaria	January 5, 2005	Phase 4
NCT01805232	University of Khartoum\|University of Kassala, Sudan\|Kassala\|Sudan	Malaria	March 2013	Phase 4
NCT00132561	London School of Hygiene and Tropical Medicine\|Institut de Recherche pour le Developpement, Senegal\|Institut de Recherche pour le Developpement\|Cheikh Anta Diop University, Senegal\|Ministry of Health, Senegal	Malaria	June 2002	Phase 2\|Phase 3
NCT02974348	University of Bamenda\|Ministry of Science and Technology of the People´s Republic of China\|National Institute for Parasitic Disease, Chinese Center for Disease Control and Prevention	Drug Resistant Malaria Due to Plasmodium Falciparum	January 2013	Phase 3

Appearance

Solid

Source

Plants
Compositae
Artemisia carvifolia Buch.-Ham. ex Roxb.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL ( 216.77 mM ; Need ultrasonic)

7.5% sodium bicarbonate : 20 mg/mL ( 52.03 mM ; Need ultrasonic)

H ₂ O : 0.67 mg/mL ( 1.74 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6013 mL	13.0066 mL	26.0132 mL
5 mM	0.5203 mL	2.6013 mL	5.2026 mL
10 mM	0.2601 mL	1.3007 mL	2.6013 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Ilamathi M, et al. Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma. Curr Top Med Chem. 2016;16(22):2453-63.
[2] Lisewski AM, et al. Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell. 2014 Aug 14;158(4):916-928.
[3] Wang B, et al. Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol Ther. 2015;16(10):1548-56.

Synonyms

Butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester

Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl) ester, [3R-(3α,5aβ,6β,8aβ,9α,10β,12β,12aR*)]-

Butanedioic acid, mono[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester

3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, butanedioic acid deriv.

Artesunic acid

Artesunate

Qinghaozhi

WR 256283

Arsumax

Dihydroqinghasu hemsuccinate

Plasmotrin

Artesunata

Cosunate

Gsunate Forte

Zysunate

Arinate

Saphnate

Armax 200

Plasmotrim

Asumax

Arsuamoon

α-Artesunic acid

Artecan

NSC 712571

HC 101B

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart